5 Burning Pharma News Stories to Top Your Week

,

As many of us enjoy well-deserved vacations, news in the Pharma industry keep on going. While you’re enjoying lighter summer fare at the dinner table, enjoy this summer salad of news in Pharma. We’ll cover successful beyond-the-pill initiatives, patient-centric organizations, Pharma mergers, as well as companies facing a loss due to biosimilars. We’ll also find out what happens when Pharma and higher education make unexpected bedfellows. Find out how that story, and other interesting news in the week, ends.

1. How Pharma Can Offer More than Pills

By Sachin H. Jain, published on Harvard Business Review

Getting a Beyond-the-Pill Initiative to Work

The term “beyond-the-pill” has been a buzzword for a while now, driven by the desire to give patients more than just medicine and financial motivations. Many of these efforts, however, fail due to lack of appropriate leadership skills, regulatory restrictions and lack of capital. An initiative that can navigate these challenges will succeed.

Read More

2. Patient Centricity Handbook

By eyeforpharma

A How-to Guide for Making Patient Centricity Second Nature

Patient-centric organizations create more value for their services and attract customers. Namely, putting patients at the center of every decision Pharma or healthcare organizations make ensures success. However, this requires an about-face for many organizations, as the mentality must shift from commercial financial success to one that puts the patient’s best interest first. Some of the core values organizations must embrace in this pursuit include transparency, partnership, continuous learning and improvement, and focus on outcomes and impact.

Read More

3. The Real Reasons for the Pharma Merger Boom

By Jen Wieczner, published on Fortune

What’s Driving Pharma M&A?

In the first six months of 2015, $221 billion in Pharma mergers rolled in. As a result of the frenzy of activity, the Pharma landscape now looks very different. Companies were fractured, split and sold off, only to be rejoined or purchased. Many experts believe the Pharma M&A change is in part due to fewer opportunities on the horizon and pressure from investors. In an effort to give revenues a boost, organizations pursue acquisitions to keep investors happy. With the available low interest rates, organizations are able to acquire cheap capital to fund their purchases. The factor driving the buys is primarily growth over several areas: revenue, share price, scaled drug distribution and earnings.

Read More

4. Biosimilars Will Cut Top 10 Vulnerable Biologics Almost in Half by 2020

By Carly Helfand, published on FiercePharmaMarketing

Pharma Braces for Big Losses

While many Pharma organizations are hopeful over near-future product launches, others are reeling from impending biosimilar competition. Branded sales are expected to take a dive for AbbVie, in particular, who depends on the drug Humira for more than half of its total revenue. By 2020, experts estimate that the top 10 biologics brands will experience a decrease in sales by $49 billion due to biosimilar competition.

Read More

5. Cambridge Researchers and Pharma in Innovative New Consortium to Develop and Study Early Stage Drugs

By University of Cambridge

Pharma and Academia: Unexpected Collaborators

It has the potential be a match made in heaven. The new Therapeutics Consortium will combine the power of intellectuals in academia with the drug-developing capabilities of the Pharma industry. The Consortium plans to connect parties in pursuit of better pharmaceuticals for some of the world’s most devastating diseases like cancer. One of the primary goals of the partnerships is to not only learn more about the inner workings of drugs, but to also innovate through the development of technologies and ideas that drive improved and new treatments.

Read More